Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

JP Morgan Downgrades Vivint Smart Home to Neutral, Raises Price Target to $12

JP Morgan analyst Paul Chung downgrades Vivint Smart Home (NYSE:VVNT) from Overweight to Neutral and raises the price target from $10 to $12.

byBenzinga Newsdesk

December 8, 2022

1 minute read

JP Morgan analyst Paul Chung downgrades Vivint Smart Home (NYSE:VVNT) from Overweight to Neutral and raises the price target from $10 to $12.

Morgan Stanley Downgrades AirSculpt Technologies to Equal-Weight, Lowers Price Target to $8.5

By Benzinga Newsdesk

Today, 2:46 AM

Morgan Stanley analyst Simeon Gutman downgrades AirSculpt Technologies (NASDAQ:AIRS) from Overweight to Equal-Weight and lowers the price target from $17 to $8.5.

AIRS

Biofrontera Inc Files Prospectus Relates To Offering And Resale From Time To Time By Selling Stockholder Of Up To 9.7M Shares Of Common Stock

By Benzinga Newsdesk

Today, 2:46 AM

-SEC Filing

BFRI

HC Wainwright & Co. Maintains Buy on RCI Hospitality Holdings, Raises Price Target to $140

By Benzinga Newsdesk

Today, 2:46 AM

HC Wainwright & Co. analyst Scott Buck maintains RCI Hospitality Holdings (NASDAQ:RICK) with a Buy and raises the price target from $120 to $140.

RICK

Gilead’s Trodelvy Under FDA Review For Pre-Treated HR+/HER2- Metastatic Breast Cancer

By Vandana Singh

Today, 2:46 AM

The FDA has accepted for review Gilead Sciences Inc’s (NASDAQ:GILD) Trodelvy (sacituzumab govitecan-hziy) for unresectable locally advanced or metastatic hormone receptor…

GILD

JP Morgan Downgrades Vivint Smart Home to Neutral, Raises Price Target to $12

Related Posts

Morgan Stanley Downgrades AirSculpt Technologies to Equal-Weight, Lowers Price Target to $8.5

Biofrontera Inc Files Prospectus Relates To Offering And Resale From Time To Time By Selling Stockholder Of Up To 9.7M Shares Of Common Stock

HC Wainwright & Co. Maintains Buy on RCI Hospitality Holdings, Raises Price Target to $140

Gilead’s Trodelvy Under FDA Review For Pre-Treated HR+/HER2- Metastatic Breast Cancer